<DOC>
	<DOCNO>NCT00559650</DOCNO>
	<brief_summary>The purpose study ass dose titration scheme , new drug ( BAY58-2667 ) give intravenously , evaluate safe help improve well-being , symptom ( e.g . breathe ) outcome decompensated heart failure . Patients live chronic heart failure risk increase number hospitalisation worsen condition ( decompensated heart failure ) . The current treatment acute heart failure consist oxygen medical treatment vasodilator positive inotropic agent ( drug , strengthen pump function heart ) limitation . Therefore need new drug treatment acute heat failure .</brief_summary>
	<brief_title>Placebo Controlled , Randomized , Double-blind , Multi-center Study Investigate Efficacy Tolerability BAY58-2667</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients decompensated chronic congestive heart failure , NYHA functional class IIIIV , either ischemic nonischemic , require hospitalization , clinical indication parenteral pharmacotherapy invasive hemodynamic monitoring ( i.e indwell SwanGanz pulmonary artery catheter ) PCWP &gt; /= 18 mmHg . Patients must clinical diagnosis CHF make least 3 month prior enrollment . Male female patient , age 18 year . Females childbearing potential . Acute denovo heart failure . Acute myocardial infarction and/or myocardial infarction within 30 day . Valvular heart disease require surgical intervention course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Acute decompensated heart failure</keyword>
	<keyword>Double blind study ,</keyword>
	<keyword>BAY58-2667</keyword>
	<keyword>Soluble guanylate cyclase activator</keyword>
</DOC>